Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1975 1
1976 1
1979 1
1986 2
1987 3
1988 1
1989 3
1990 5
1991 2
1992 2
1993 1
1994 4
1995 4
1996 7
1997 7
1998 4
1999 5
2000 2
2001 8
2002 15
2003 17
2004 25
2005 34
2006 31
2007 44
2008 59
2009 68
2010 79
2011 84
2012 112
2013 105
2014 83
2015 104
2016 91
2017 113
2018 116
2019 109
2020 97
2021 130
2022 116
2023 116
2024 117
2025 110
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,806 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: choi ch. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Among authors: choi ch. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
Authors' Reply.
Lim S, Chung YE, Seo JH, Choi CH, Lee Y, Kato K, Lee YL, Chen YL. Lim S, et al. Among authors: choi ch. J Minim Invasive Gynecol. 2025 Aug 11:S1553-4650(25)00295-X. doi: 10.1016/j.jmig.2025.08.007. Online ahead of print. J Minim Invasive Gynecol. 2025. PMID: 40803505 No abstract available.
Heteroatom-Substituted Reflashed Graphene.
Scotland P, Eddy L, Chen J, Chen W, Beckham JL, Wyss KM, Choi CH, Advincula PA, Lathem A, Onah OE, Han Y, Tour JM. Scotland P, et al. Among authors: choi ch. ACS Nano. 2025 Apr 1;19(12):11987-11998. doi: 10.1021/acsnano.4c16959. Epub 2025 Mar 21. ACS Nano. 2025. PMID: 40117566
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Grisham R, et al. Among authors: choi ch. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005919. doi: 10.1136/ijgc-2024-005919. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39375168 Free article.
33 Unresolved Questions in Nanoscience and Nanotechnology.
Mirkin CA, Petrosko SH, Artzi N, Aydin K, Biaggne A, Brinker CJ, Bujold KE, Cao YC, Chan RR, Chen C, Chen PC, Chen X, Chevalier OJGL, Choi CHJ, Crooks RM, Dravid VP, Du JS, Ebrahimi SB, Fan H, Farha OK, Figg CA, Fink TD, Forsyth CM, Fuchs H, Geiger FM, Gianneschi NC, Gibson KJ, Ginger DS, Guo S, Hanes JS, Hao L, Huang J, Hunter BM, Huo F, Hwang J, Jin R, Kelley SO, Kempa TJ, Kim Y, Kudruk S, Kumari S, Landy KM, Lee KB, Leon NJ, Li J, Li Y, Li Z, Liu B, Liu G, Liu X, Liz-Marzán LM, Lorch JH, Luo T, Macfarlane RJ, Millstone JE, Mrksich M, Murphy CJ, Naik RR, Nel AE, Oetheimer C, Hedlund Orbeck JK, Park SJ, Partridge BE, Peppas NA, Personick ML, Raj A, Ramani N, Ross MB, Ross SB, Sargent EH, Sengupta T, Schatz GC, Seferos DS, Seideman T, Seo SE, Shen B, Shim W, Shin D, Simon U, Sinegra AJ, Smith PT, Spokoyny AM, Stang PJ, Stegh AH, Stoddart JF, Swearer DF, Tan W, Teplensky MH, Thaxton CS, Walt DR, Wang MX, Wang Z, Wei WD, Weiss PS, Winegar PH, Xia Y, Xie Y, Xu X, Yang P, Yang Y, Ye Z, Yoon KR, Zhang C, Zhang H, Zhang K, Zhang L, Zhang X, Zhang Y, Zheng Z, Zhou W, Zhu S, Zhu W. Mirkin CA, et al. Among authors: choi chj. ACS Nano. 2025 Sep 16;19(36):31933-31968. doi: 10.1021/acsnano.5c12854. Epub 2025 Sep 4. ACS Nano. 2025. PMID: 40905551 Free article.
Chlorhexidine-releasing orthodontic elastomerics.
Jeon HS, Choi CH, Kang SM, Kwon HK, Kim BI. Jeon HS, et al. Among authors: choi ch. Dent Mater J. 2015;34(3):321-6. doi: 10.4012/dmj.2014-216. Epub 2015 Apr 23. Dent Mater J. 2015. PMID: 25904169 Free article.
1,806 results